Literature DB >> 1775933

Intrinsic factor secretion and cobalamin absorption. Physiology and pathophysiology in the gastrointestinal tract.

H P Festen1.   

Abstract

Intrinsic factor is produced by the gastric parietal cell. Its secretion is stimulated via all pathways known to stimulate gastric acid secretion: histamine, gastrin, and acetylcholine. There is, however, a different mode of secretion for both substances: atropine, vagotomy, and H2 receptor antagonists inhibit both intrinsic factor and acid secretion, but secretin and the hydrogen-potassium ATPase antagonist omeprazole have no effect on intrinsic factor while substantially reducing acid secretion. Cobalamin in food is bound to animal protein. Cobalamin deficiency due to inadequate dietary intake is rarely seen in extreme vegetarians (vegans). In the stomach cobalamin is liberated from its protein binding by peptic digestion and bound to R-proteins. Hypochlorhydria or achlorhydria, whether medically induced or not, may impair cobalamin uptake. The cobalamin-R-protein complex is split by pancreatic enzymes in the duodenum, where cobalamin is bound to intrinsic factor. Pancreatic insufficiency may lead to cobalamin deficiency. Lack of intrinsic factor is the commonest cause of cobalamin deficiency; very rarely, aberrant forms of intrinsic factor are produced, but the clinical syndrome is similar. Gram-negative anaerobe bacteria bind the cobalamin-intrinsic factor complex, and bacterial overgrowth of the small intestine diminishes cobalamin resorption. Parasitic infections with fish tape-worm and Giardia lamblia are also associated with cobalamin malabsorption. The cobalamin-intrinsic factor complex binds to the ileal receptors in the terminal ileum. Cobalamin absorption may be impaired after resection or by diseases affecting more than 50 cm of the terminal ileum, such as Crohn's disease, coeliac disease, tuberculosis, lymphoma or radiation. There is clearly a wide diversity in the aetiology of cobalamin deficiency, which requires a versatile diagnostic approach.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1775933     DOI: 10.3109/00365529109111222

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  18 in total

Review 1.  Age-related changes in cobalamin (vitamin B12) handling. Implications for therapy.

Authors:  H Nilsson-Ehle
Journal:  Drugs Aging       Date:  1998-04       Impact factor: 3.923

2.  Gastric acid secretion and vitamin B12 absorption after vertical Roux-en-Y gastric bypass for morbid obesity.

Authors:  C D Smith; S B Herkes; K E Behrns; V F Fairbanks; K A Kelly; M G Sarr
Journal:  Ann Surg       Date:  1993-07       Impact factor: 12.969

Review 3.  Adverse effects of long-term proton pump inhibitor therapy.

Authors:  Edward Sheen; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2011-03-02       Impact factor: 3.199

Review 4.  Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Curr Gastroenterol Rep       Date:  2010-12

5.  Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications.

Authors:  Joel J Heidelbaugh
Journal:  Ther Adv Drug Saf       Date:  2013-06

6.  Prospective evaluation of gastric acid secretion and cobalamin absorption following gastric bypass for clinically severe obesity.

Authors:  K E Behrns; C D Smith; M G Sarr
Journal:  Dig Dis Sci       Date:  1994-02       Impact factor: 3.199

7.  Evaluation of Vitamin B12 Monitoring in Patients on Concomitant Metformin and Proton Pump Inhibitors.

Authors:  Logan Chappell; Stephen A Brown; Terri M Wensel
Journal:  Innov Pharm       Date:  2020-10-28

8.  Letter to Editor.

Authors:  Amosy E M'Koma
Journal:  Adv Enzyme Res       Date:  2013

9.  Metformin With Either Histamine H2-Receptor Antagonists or Proton Pump Inhibitors: A Polypharmacy Recipe for Neuropathy via Vitamin B12 Depletion.

Authors:  Matthew J Zdilla
Journal:  Clin Diabetes       Date:  2015-04

Review 10.  Metformin and Micronutrient Status in Type 2 Diabetes: Does Polypharmacy Involving Acid-Suppressing Medications Affect Vitamin B12 Levels?

Authors:  Michael Wakeman; David T Archer
Journal:  Diabetes Metab Syndr Obes       Date:  2020-06-18       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.